Healthcare Industry News: Roche
News Release - January 8, 2010
Cephalon Executive Vice President of Worldwide Pharmaceutical Operations Robert Roche to Resign PositionFRAZER, Pa., Jan. 8 (Healthcare Sales & Marketing Network) -- Cephalon, Inc., (Nasdaq: CEPH) today announced that effective February 5, 2010, Robert P. Roche, Jr., Executive Vice President of Worldwide Pharmaceutical Operations, will resign his position with the company to pursue other longstanding interests. During his tenure, Mr. Roche established and grew the Cephalon sales and marketing organization into a global business that exceeded $2 billion in annual sales revenue. The company will announce plans for its leadership and the commercial organization in the near future. Additionally, the global commercial leadership team, Alain Aragues, President of Cephalon Europe, Paul Li, Senior Vice President of International Pharmaceutical Operations, and Robert Repella, Senior Vice President of U.S. Pharmaceutical Operations, will continue to lead their respective organizations.
"Bob Roche made a tremendous contribution to the worldwide commercial success of Cephalon. On behalf of the board of directors and executive team, I want to express my appreciation for his 15 years of excellent service and leadership in establishing Cephalon as one of the leading biopharmaceutical companies in the world," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "Bob built strong global sales and marketing organizations and we remain enthusiastic about our growth opportunities and the future of our company."
Since 1995, Mr. Roche has led the worldwide commercial organization which now has more than 30 products. He was promoted to Senior Vice President, Worldwide Pharmaceutical Operations, in 2000, and named an Executive Vice President in 2005. Before joining Cephalon, Mr. Roche served as Director and Vice President, Worldwide Strategic Product Development, for SmithKline Beecham's central nervous system and gastrointestinal products business. He also was managing director of SmithKline's pharmaceutical operations in the Philippines. He also held senior marketing positions in Canada and Spain and had product planning responsibilities for SmithKline in Latin America.
Mr. Roche serves as a member of the board of directors for Intercept Pharmaceuticals.
About Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. A member of the Fortune 1000 and the S&P 500 Index, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota.
Cephalon has a growing presence in Europe, the Middle East and Africa. The Cephalon European headquarters and pre-clinical development center are located in Maisons-Alfort, France, just outside of Paris. Key business units are located in England, Ireland, France, Germany, Italy, Spain, the Netherlands for the Benelux countries, and Poland for Eastern and Central European countries. Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology.
The company's proprietary products in the United States include: NUVIGIL(R) (armodafinil) Tablets [C-IV], TREANDA(R) (bendamustine hydrochloride) for Injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide) injection, GABITRIL(R) (tiagabine hydrochloride), PROVIGIL(R) (modafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.